Mozistobart Zoratolimod

**Semantic type:** Pharmacologic Substance

**Definition:** A toll-like receptor (TLR) agonist antibody conjugate (TRAAC) composed of mozistobart, a humanized immunoglobulin G1-kappa (IgG1k) monoclonal antibody that is directed against the B-cell restricted antigen CD22, conjugated at one glutamine residue with zoratolimod, an unmethylated oligonucleotide-based TLR 9 agonist (T-CpG), with potential immunostimulating and antineoplastic activities. Upon intravenous administration of mozistobart zoratolimod, the mozistobart moiety targets and binds to CD22 on B-cells, including tumor-infiltrating B-cells, thereby systemically delivering zoratolimod to B-cells. In turn, the zoratolimod moiety binds to the TLR9 receptor expressed on tumor-infiltrating B-cells in the tumor microenvironment (TME), which activates B-cells and induces TLR-mediated signaling. This activates innate and adaptive immune responses and leads to a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. TLR9, a member of the TLR family, plays a fundamental role in pathogen recognition and activation of the innate immune system. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.

**Synonyms:** - Anti-CD22-T-CpG Conjugate TAC-001 - MOZISTOBART ZORATOLIMOD - TAC 001 - TAC-001 - TAC001 - TLR9 Agonist/Anti-CD22 Antibody Conjugate TAC-001 - TRAAC TAC-001 - Toll-like Receptor Agonist Antibody Conjugate TAC-001